Social Icons

Showing posts with label CapitalStars Reviews. Show all posts
Showing posts with label CapitalStars Reviews. Show all posts

Thursday, 10 May 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 10 MAY 2018

CAPITALSTARS


CS OPENING BELL:
NIFTY SPOT UP 23 @ 10764
SENSEX UP 100 @ 35420
BANK NIFTY FUTURES UP 55  @ 26138
HAPPY TRADING!!!!!!!!!!!


CS NIFTY FUTURES (MAY ) OVERVIEW

TREND BEARISH
RES2: 10875
RES 1:10810
SUP1:10750
SUP2:10700



CS BANK NIFTY FUTURES (MAY ) OVERVIEW

TREND BEARISH
RES 2: 26350
RES 1: 26250
SUP1: 26050
SUP2: 25950

visit us: www.capitalstars.com/




call on:9977499927

O731-6690000


Get more details here:-

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.



CapitalStars Investment Adviser: SEBI Registration Number: INA000001647



Tuesday, 30 January 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

Capitalstars Updates: Top Corporate News :- 30 Jan 2018

Capitalstars Updates:  Top Corporate News

Top Headlines Of The Day:- 30 Jan 2018

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets
KPIT and Birlasoft to come together to create two entities
Mylan and Biocon receive positive CHMP opinion for Insulin Glargine
Amber Enterprises lists at 38% premium to issue price
HCL Tech gets 5-year order from Cadent for IT Infra services

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets
Jubilant Life Sciences has announced that its material wholly owned subsidiary Jubilant Pharma Limited has received Abbreviated New Drug Application (ANDA) final approval for Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg. This is a generic version of Kapvay of Concordia. It is used for the treatment of attention deficit hyperactivity disorder (ADHD).
As on December 31, 2017, Jubilant had a total of 86 ANDAs for Oral Solids filed in the US of which 56 had been approved and 12 Injectable filings of which 10 had been approved. This is the eighth USFDA approval in FY18.

Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg had annual sales of ~USD 66 million in the US as per IMS MAT Jun 2017. 

KPIT and Birlasoft to come together to create two entities
KPIT Technologies had informed the exchanges that its board had approved a draft composite scheme for amalgamation of Birlasoft (India) with KPIT. The second leg of the transaction would involve demerger of the engineering business of the company into KPIT Engineering Limited (KEL), a wholly owned subsidiary of the company and will be renamed as KPIT Technologies Limited.
According to the arrangement, shareholders of Birlasoft will receive 22 equity shares of the combined KPIT -Birlasoft for every nine equity shares of Birlasoft. the combined KPIT-Birlasoft will be engaged in the ITSS Business, and pursuant to the Proposed Demerger, KEL's shares will be listed and shareholders of combined KPIT-Birlasoft will receive one share of KEL for each share they hold in the combined KPIT-Birlasoft.

Mylan and Biocon receive positive CHMP opinion for Insulin Glargine
Biocon has announced that it, along with its partner Mylan, has received a positive opinion from Europen Medical Agency’s (EMA) - Committee for Medicinal Products for Human Use (CHMP) - for insulin Glargine. CHMP has also recommended approval to Insulin Glargine, which will be sold under brand Semglee.
There are ~60m people affected by diabetes in Europe with an increasing prevalence in the region. Insulin Glargine is a biosimilar, which will be available for commercialization once it receives EMA approval.
Biocon and Mylan are also awaiting approval for Insulin Glargine in Australia, Canada, and the US and are planned for key Emerging Markets.

Amber Enterprises lists at 38% premium to issue price
Amber Enterprises listed at a significant premium of 38% to its issue price of Rs855-859 and is currently trading at Rs1, 187.2.
The IPO offer consisted of Fresh Issue of 55.3 lakh shares (aggregating up to ~Rs475cr) at the upper end of the price band. It also includes an offer for sale of up to 14.6 lakh shares (Rs125cr) by the promoters. The issue proceeds will be used for pre-payment or repayment of borrowings (~Rs400cr) and for other general corporate purposes (~Rs75cr).

HCL Tech gets 5-year order from Cadent for IT Infra services
HCL Technologies (HCL) announced a five-year IT infrastructure services and application management contract with Cadent, the UK’s largest gas distribution network. The ground-breaking ‘cloud first’ multi-service deal will see HCL provide integrated public cloud hosting and SAP and Application Maintenance Services, including the migration of a significant applications portfolio to Amazon Web Services (AWS) public cloud. In addition, HCL will provide IT Service Management, Service Desk and Managed Workplace Services.
HCL will deliver these services to support Cadent’s business operations which distributes gas to 11 million homes and businesses in the North West, Midlands, East and South East of England. HCL will provide MWS support to approximately 4,500 staff; including 3,500 field based-engineers who work across the company’s 65 regional depots.

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647





Monday, 29 January 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

Capitalstars Updates: Top Corporate News :- 29 Jan 2018

Capitalstars Updates:  Top Corporate News
Top Headlines Of The Day :- 29 Jan 2018
Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
DLF is looking to launch QIP of shares by April, 2018
Idea Cellular seeks government approval for raising FDI limit to 100%
Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
DMart rallies 5% after announcing Q3FY18 results. In Q3FY18, its revenue grew by 22.6% yoy to Rs4, 095cr. EBITDA came in at Rs422cr, up 46.3% yoy . EBITDA margin expanded by 167bps yoy to 12.3% due to an improvement in sales mix and efficiency of centralized procurement. Adjusted PAT increased by 65.8% yoy to Rs252cr.
Board has also approved acquisition of 50.8% paid-up share capital of Avenue E-Commerce Limited for Rs49.2cr. Post-acquisition it will become wholly owned subsidiary. Heavy discounts to attract price sensitive customers and losses of the e-commerce entity will offset the margin gains.


Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Cipla, Aurobindo and Strides Shasun have received final approval for their Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the USFDA. This is a generic version of Gilead Sciences' Viread Tablets, 300mg which is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults. The final approval means that product is available for immediate commercialization in the US.
Viread 300mg tablets had annual US sales of approximately $725-750mn as per IMS Health. An orange book search on USFDA website indicates that Aurobindo, Cipla, Teva, Macleods Pharmaceuticals and Strides Shasun, all have received approval for this drug on January 26, 2018. Approval for five different filers on the same day is likely to see competition for the Viread 300mg tablets.


Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
Havells is setting-up a new facility at Ghiloth, Neemrana, Rajasthan to manufacture consumer durables, as per the BSE filing. The total estimated cost for the project is Rs360cr (ex-land cost, as the company already owns the land), spread over a period of 3 years. The total investment will be funded through a mix of internal accruals and borrowings. Company expects to start the production from Q3FY19E.
For this investment, the company will be entitled to investment subsidy under the M-SIPS (Modified Special Incentive Package Scheme) introduced by MEITY and also for various tax/ levies and other benefits from the State Government of Rajasthan.


DLF is looking to launch QIP of shares by April, 2018
DLF is looking to launch its qualified institutional placement (QIP) of shares by April 2018, according to a media report.
DLF has already received approval from shareholders to sell 173-million equity shares, which will be determined by the formula laid down by the market regulator Securities and Exchange Board of India. The company may raise Rs4500-5000cr from the QIP.


Idea Cellular seeks government approval for raising FDI limit to 100%
Telecom operator Idea Cellular has made an application to the DIPP (Department of Industrial Policy and Promotion) for raising the FDI limit in Idea to 100%. Foreign investors holdings in Idea Cellular stood at ~27% stake as on December 2017. While 100% FDI is allowed in telecom companies, investments under the automatic route are allowed up to 49%.
At present, Idea Cellular is in the process of merging its telecom business with the Indian unit of Vodafone. As per latest industry data from Trai, Idea and Vodafone jointly have 40.5cr mobile subscribers. This would potentially give the joint entity the largest subscriber base in the Indian telecom segment. Vodafone is expected to hold around 47.5% stake in the merged entity and rest will be owned by Idea and its promoter Aditya Birla Group.


Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647




Tuesday, 23 January 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CapitalStars Kamyabi Ki Raah On CNBC Awaaz - 23 Jan 2018

CapitalStars Kamyabi Ki Raah On CNBC Awaaz - 23 Jan 2018


CapitalStars Award Winning, SEBI registered, ISO certified investment advisory company. We provide intraday & positional services in equity , derivative ,commodity & currency. Our research team is highly skilled & experienced 

Please Contact 0731-6690000.

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647



Saturday, 20 January 2018

expr:content='data:blog.blogId' itemprop='blogId'/>

CapitalStars On CNBC Awaaz, Kamyabi Ki Raah - 20 Jan 2018

CapitalStars On CNBC Awaaz, Kamyabi Ki Raah - 20 Jan 2018


CapitalStars Award Winning, SEBI registered, ISO certified investment advisory company. We provide intraday & positional services in equity , derivative ,commodity & currency. Our research team is highly skilled & experienced 

Contact Us 0731-6690000.

CLICK HERE FOR GET DETAILS & JOIN OUR BEST ADVISORY  -
 CAPITALSTARS CALL US  9977499927
Equity Tips , Intraday Stock Tips , FreeTrading Tips  , Sebi Registered advisory Company , Capitalstars Video Gallery

Investment  & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Monday, 18 December 2017

expr:content='data:blog.blogId' itemprop='blogId'/>

CapitalStars Market Ad On CNBC Awaaz, Pehla Kadam Date 18 Dec 2017

CapitalStars Market Ad On CNBC Awaaz, Pehla Kadam Date 18 Dec 2017


CapitalStars Award Winning, SEBI registered, ISO certified investment advisory company. We provide intraday & positional services in equity , derivative ,commodity & currency. Our research team is highly skilled & experienced please contact 0731-6690000.


CLICK HERE FOR GET DETAILS & JOIN OUR BEST ADVISORY  -
 CAPITALSTARS CALL US  9977499927
Equity Tips , Intraday Stock Tips , FreeTrading Tips  , Sebi Registered advisory Company , Capitalstars Video Gallery

Investment  & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

expr:content='data:blog.blogId' itemprop='blogId'/>

CapitalStars Market Ad On CNBC Awaaz , Commodity Call Date 18 Dec 2017

CapitalStars Market Ad On CNBC Awaaz, Commodity Call Date 18 Dec 2017



CapitalStars Award Winning, SEBI registered, ISO certified investment advisory company. We provide intraday & positional services in equity , derivative ,commodity & currency. Our research team is highly skilled & experienced please contact 0731-6690000.


CLICK HERE FOR GET DETAILS & JOIN OUR BEST ADVISORY  -
 CAPITALSTARS CALL US  9977499927
Equity Tips , Intraday Stock Tips , FreeTrading Tips  , Sebi Registered advisory Company , Capitalstars Video Gallery

Investment  & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance. CapitalStars Investment Adviser: SEBI Registration Number: INA000001647



Friday, 20 May 2016

expr:content='data:blog.blogId' itemprop='blogId'/>

TOP CORPORATE NEWS- 20 May 2016


IRB Infra Q4 consolidated net profit at Rs151 cr
IRB Infrastructure Developers has announced the following Q4 & FY16 results for the quarter & year ended March 31, 2016:
Standalone
For the Quarter ended March 31, 2016
The Company has posted a net profit of Rs94.37 crore Vs Rs12.33 crore (YoY).
Total Income increased to Rs972.66 crore Vs Rs529.96 crore (YoY).

Lupin cracks as FDA overhang continues
Shares of Lupin cracked 9% to Rs1505 on NSE despite strong outlook as the FDA overhang continues; retain Hold with PT revised to Rs1,850
Strong operating performance:
For Q4FY2016, Lupin’s sales grew by 35.8% to Rs4,181.2 crore; operating profit improved by 73.2% to Rs1,367.4 crore and profit grew of 47.5% to Rs807 crore.
The strong set of numbers was aided by two months’ exclusivity sales from gGlumetza coupled with price hikes in Fortamet.
Profit was affected (compared with growth in operating profit) due to higher tax rate of 33.6% in Q4FY2016 against 19.5% in Q4FY2015. Also, the interest cost has gone up due to increase in debt (taken for funding Gavis acquisition).

Pidilite Inds Q4 consolidated net profit up 89% (YoY)
Pidilite Industries Ltd has announced the Q4 & FY16 audited following results for the quarter & year ended March 31, 2016:
Standalone
For the Quarter ended March 31, 2016 (YoY)
The Company has posted a net profit of Rs115.04 crore Vs Rs77.22 crore.
Total Income increased to Rs1101.10 crore Vs Rs975.93 crore.

Allcargo Logistics rallies on plans to buy majority stake in CCI
Shares of Allcargo Logistics surged 5.4% to Rs153.10 on BSE on back of reports that the company has plans to buy majority stake in CCI for Rs130 crore – Positive for Allcargo Logistics.
The deal will lead to the formation of a new entity in which Allcargo will hold 62%, while the rest is held by CCI.

Force Motors to invest Rs300 cr in FY17 for expansion
Force motors has announced an expansion plan for FY17 with an investment of Rs300 Cr towards new facilities and product enhancement.
The company which supplies engines to marque luxury car maker like BMW and Mercedes is planning to set up a new plant in Chakan (Pune) for manufacturing engines for Mercedes Benz with the investment of Rs150 crore.

Our Some Best Services Read it Here…
 CapitalStars Financial Research Financial Advisory Services 

www.capitalstars.com | T:+91-731-6790000,6669900


Thursday, 20 August 2015

expr:content='data:blog.blogId' itemprop='blogId'/>

Corporate News For Today 20-Aug-2015

·         Aurobindo gets final approval for Omeprazole
Aurobindo Pharma announced that the company has received the final approval from the US Food & Drug Administration ( USFDA) to manufacture and market Omeprazole Delayed-release Capsules USP, 10mg, 20mg and 40mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Prilosec® Delayed-release Capsules, 10mg, 20mg and 40mg of AstraZeneca Pharmaceuticals.

·          Aurobindo receives USFDA approval for Ibandronate
Aurobindo Pharma announced that the company has received final approvals from the US Food & Drug Administration ( USFDA) to manufacture and market Ibandronate Sodium Injection, 3mg/3mL (1mg/mL).
Ibandronate Sodium Injection, 3mg/3mL (1mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva® Injection, 3mg/3mL (1mg/mL) of Hoffmann-La Roche, Inc. Ibandronate Sodium Injection is indicated for the treatment of osteoporosis in postmenopausal women.
                                                                                
·         Crude oil declines further; Brent at $47
Crude oil declined further; Brent at $47 and WTI at $ 40, new low - Positive for OMC’s , Paints, Lubricants and Tyre companies .Crude Oil ( Brent) has slipped again and is now trading below 5 year low at $ 46.92, while WTI Oil is hovering around $40. As a result the industries which use crude and its derivatives are expected to be beneficial. Positive for OMCs (HPCL, BPCL), Paint (Asian Paints) and lubricants (Castrol, Gulf oil lubricant)
·         Lupin gets USFDA nod for Fenofibrate tablets; stk jumps
Shares of Lupin surged over 8%, touching to Rs1939.9, after pharma major said it has received approval from USFDA for Fenofibrate tablets in dosages of 160 mg and 54 mg. Fenofibrate is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.

·         Ratnamani Metals bags new order worth Rs159.40 cr
Ratnamani Metals & Tubes has announced that the Company has bagged an order for supply of coated CS pipes from Reliance Gas Pipelines amounting to Rs159.40 crores (net of taxes and duties) to be completed in current financial year.

·         Somi Conveyor Beltings receives orders worth Rs40.14 cr
Somi Conveyor Beltings said that it has received purchase orders worth Rs40.137 crore from BHEL, L&T and ThyssenKrupp Industries. The company will supply conveyor belts and related material of various specifications, it said. The company has bagged order worth Rs14.751 crore from Bharat Heavy Electricals ( BHEL). The order worth Rs14.164 crore was received from Larsen & Tourbo ( L&T), it said.
In addition, ThyssenKrupp Industries India issued order worth Rs 11.222 million to the company.
                                                                                                   
·         JSW Steel to invest Rs5000 cr on capital expenditure
JSW Steel has said that it is planning to invest about Rs5,000 crore on various capital expenditure projects in this fiscal ending March 2016, as per reports.  Commenting on the issue, JSW Steel Chairman and Managing Director Sajjan Jindal told the media, 'The company is expected to invest approximately Rs 5,000 crore during FY16 on various capital expenditure programmes.'
                                                    
·         Sun Pharma gets USFDA approval for Ximino

Sun Pharma gets USFDA approval for Ximino: Positive for the company .Sun Pharma gets US FDA approval for Supplemental New Drug Application (sNDA) for Ximino. This approval further strengthens the Company’s branded dermatology portfolio in the US. It expects Ximino TM extended-release capsules to be available for patients during the fourth quarter of 2015.

Monday, 17 August 2015

expr:content='data:blog.blogId' itemprop='blogId'/>

INDIAN BENCHMARKS For Today

INDIAN BENCHMARKS , Monday Blues: Shaky start to the Week

INDIAN EQUITY BENCHMARKS fell on Monday, led by selling in blue chip stocks as weak Asian markets, a lacklustre parliament session and the absence of any positive earnings trigger weighed on sentiment. The S&P  BSE Se nsex and CNX Nifty ended 0.67%-0.48% lower each.

Headlines for the day:

·         Nitin Fire jumps 10%; Amitabh Bachchan buys stake
·         Exports contract to 10.3% in July
·         Punj Lloyd tanks post Q1FY2016 earnings


The crucial resistance for Nifty is now seen at 8555 and above this 8595. Support for the immediate term is now placed at 8455 and next support will be 8415.
expr:content='data:blog.blogId' itemprop='blogId'/>

Opening Bell 17-Aug-2015

CAPITALSTARS OPENING BELL:
NIFTY SPOT UP 10@8530
SENSEX DOWN 15@28052
BANK NIFTY FUTURES UP 6@18798

HAPPY TRADING
+917316790000

CS NIFTY FUTURES (AUG) OVERVIEW
TREND MIXED TO BULLISH
RES2:8595
RES 1:8555     
SUP1:8502
SUP2:8475

+917316790000

CS BANK NIFTY FUTURES (AUGUST) OVERVIEW
TREND MIXED TO BULLISH
RES 2:18975
RES 1:18875
SUP1:18625
SUP2:18525


+917316790000
 

Do U Want !!!!

Our Special Services

sensex-nifty-charts

 
Blogger Templates